Return to Home Incidence > Table

Incidence Rates Table

Data Options
Comparison Options

Incidence Rate Report by State

Esophagus (Late Stage^), 2018-2022

All Races (includes Hispanic), Both Sexes, All Ages

Sorted by Percentlate

State
 sort alphabetically by name ascending
Age-Adjusted Incidence Rate
cases per 100,000
(95% Confidence Interval)
 sort by rate descending
CI*Rank
(95% Confidence Interval)
 sort by CI rank descending
Average Annual Count
 sort by count descending
Percent of Cases with Late Stage
 sort by percent late ascending
North Dakota 2 3.5 (3.0, 4.1) 18 (3, 41) 33 76.4
South Dakota 2 4.2 (3.7, 4.8) 3 (1, 20) 48 75.1
Wisconsin 2 4.0 (3.8, 4.2) 8 (3, 14) 316 74.4
Indiana 2 4.1 (3.9, 4.3) 5 (2, 10) 351 74.3
Maine 2 5.3 (4.9, 5.8) 1 (1, 2) 114 74.2
Montana 2 3.7 (3.3, 4.2) 11 (2, 32) 57 74.0
West Virginia 2 4.5 (4.1, 4.9) 2 (1, 8) 119 73.0
Hawaii 7 2.5 (2.2, 2.8) 44 (34, 51) 50 72.5
Iowa 7 4.1 (3.9, 4.4) 4 (2, 12) 175 72.2
Pennsylvania 2 3.8 (3.7, 4.0) 9 (5, 15) 703 71.7
Connecticut 7 3.3 (3.1, 3.5) 23 (14, 35) 164 71.3
Rhode Island 2 3.5 (3.1, 4.0) 16 (3, 36) 53 71.0
Massachusetts 2 3.6 (3.5, 3.8) 13 (8, 21) 340 70.8
North Carolina 2 3.1 (2.9, 3.2) 31 (21, 37) 416 70.7
Missouri 2 3.7 (3.5, 3.9) 12 (6, 21) 299 70.2
Oregon 2 3.3 (3.1, 3.5) 22 (14, 34) 187 70.2
Illinois 7 3.5 (3.4, 3.6) 19 (12, 24) 566 70.0
Ohio 2 4.0 (3.9, 4.1) 6 (3, 11) 631 69.2
New York 7 2.9 (2.8, 3.0) 38 (31, 41) 755 69.1
Colorado 2 2.7 (2.5, 2.9) 41 (33, 47) 182 69.0
Louisiana 7 3.2 (3.0, 3.4) 24 (16, 36) 186 69.0
Maryland 2 2.7 (2.5, 2.8) 42 (34, 46) 211 69.0
Kansas 2 3.2 (2.9, 3.5) 25 (14, 39) 116 68.5
New Hampshire 2 4.0 (3.6, 4.4) 7 (2, 20) 84 68.4
Utah 7 2.3 (2.0, 2.5) 50 (41, 51) 70 68.1
Minnesota 2 3.6 (3.4, 3.8) 14 (8, 24) 259 67.9
New Jersey 7 2.8 (2.7, 2.9) 39 (32, 43) 336 67.7
Alaska 2 3.5 (2.9, 4.2) 17 (2, 42) 29 67.4
Virginia 2 2.9 (2.7, 3.0) 36 (28, 42) 311 67.4
Washington 1 3.2 (3.0, 3.4) 26 (17, 35) 303 67.3
Idaho 7 3.1 (2.8, 3.4) 30 (13, 42) 71 67.2
California 7 2.3 (2.3, 2.4) 48 (44, 51) 1,093 66.9
Georgia 7 2.9 (2.7, 3.0) 37 (29, 42) 361 66.8
Michigan 2 3.6 (3.4, 3.7) 15 (10, 22) 490 66.5
Kentucky 7 3.8 (3.5, 4.0) 10 (4, 20) 220 66.3
Vermont 2 3.4 (2.9, 4.0) 20 (3, 42) 34 66.3
South Carolina 2 3.0 (2.8, 3.2) 33 (21, 40) 214 66.2
Mississippi 2 3.2 (2.9, 3.4) 28 (15, 39) 120 65.7
Nebraska 2 3.2 (2.9, 3.5) 27 (12, 41) 77 65.4
Oklahoma 2 3.3 (3.1, 3.5) 21 (13, 34) 161 64.3
Arkansas 2 3.1 (2.9, 3.4) 29 (16, 41) 124 64.2
Delaware 2 3.0 (2.6, 3.4) 34 (14, 47) 43 63.6
Tennessee 2 3.1 (2.9, 3.2) 32 (20, 38) 275 63.4
Texas 7 2.5 (2.4, 2.6) 43 (41, 48) 780 62.3
Wyoming 2 2.9 (2.4, 3.6) 35 (9, 51) 22 60.8
Florida 2 2.8 (2.7, 2.9) 40 (34, 43) 898 60.1
Arizona 2 2.4 (2.3, 2.6) 46 (41, 51) 232 59.0
District of Columbia 2 2.1 (1.7, 2.7) 51 (34, 51) 15 57.9
New Mexico 7 2.3 (2.0, 2.6) 49 (41, 51) 66 57.8
Alabama 2 2.4 (2.3, 2.6) 45 (40, 51) 162 54.8
Nevada 2 2.4 (2.2, 2.6) 47 (39, 51) 93 51.7
Puerto Rico 2 1.2 (1.0, 1.3) N/A 59 41.5

Notes:
Created by statecancerprofiles.cancer.gov on 03/30/2026 1:18 pm.

State Cancer Registries may provide more current or more local data.

† Incidence rates (cases per 100,000 population per year) are age-adjusted to the 2000 US standard population (SEER areas use 20 age groups and NPCR areas use 19 age groups). Rates are for invasive cancer only (except for bladder cancer which is invasive and in situ) or unless otherwise specified. Rates calculated using SEER*Stat. Population counts for denominators are based on Census populations as modified by NCI. The US Population Data File is used for SEER and NPCR incidence rates.

Rates are computed using cancers classified as malignant based on ICD-O-3. For more information see malignant.html.

^ Late Stage is defined as cases determined to be regional or distant. Due to changes in stage coding, Combined Summary Stage with Expanded Regional Codes (2004+) is used for data from Surveillance, Epidemiology, and End Results (SEER) databases and Merged Summary Stage is used for data from National Program of Cancer Registries databases. Due to the increased complexity with staging, other staging variables maybe used if necessary.

⋔ Results presented with the CI*Rank statistics help show the usefulness of ranks. For example, ranks for relatively rare diseases or less populated areas may be essentially meaningless because of their large variability, but ranks for more common diseases in densely populated regions can be very useful. The rates used in CI*Rank are all age-adjusted to the 2000 US standard population using 19 age groups for SEER and NPCR areas. More information about methodology can be found on the CI*Rank website.

Source: SEER and NPCR data. For more specific information please see the table.

Data for United States does not include Puerto Rico.

CI*Rank data for Puerto Rico is not available.

Return to Top